Status:
COMPLETED
Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis
Lead Sponsor:
Nantes University Hospital
Conditions:
Relapsing-remitting Multiple Sclerosis
Eligibility:
All Genders
18-45 years
Phase:
PHASE3
Brief Summary
Therapeutic strategies for multiple sclerosis (MS) are essentially based on the use of immunomodulatory agents such as interferon b and glatirmere acetate, but their efficacy is quite limited, they ar...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Relapsing remitting MS with diagnosis defined by the McDonald criteria (McDonald et al., 2001) with no current disease modifying therapy (interferon, copaxone or immunosuppressant drugs) since at least 3 months and an EDSS score \< 5.
- At least one gadolinium positive lesion on the MRI of the selection phase is needed.
- No current statin therapy.
- Normal renal and hepatic biological tests.
- No current pregnancy
Exclusion
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00200655
Start Date
December 1 2004
End Date
November 1 2007
Last Update
April 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nantes University Hospital
Nantes, France, 44093